Have a feature idea you'd love to see implemented?
Let us know!
KRYS Krystal Biotech Inc
Price (delayed)
$182.29
Market cap
$5.24B
P/E Ratio
99.07
Dividend/share
N/A
EPS
$1.84
Enterprise value
$4.88B
Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.
Highlights
The revenue has grown by 45% since the previous quarter
The gross profit rose by 44% QoQ
The company's quick ratio has shrunk by 63% YoY and by 17% QoQ
The net income has plunged by 51% from the previous quarter
Key stats
What are the main financial stats of KRYS
Market
Valuations
Earnings
Shares outstanding
28.76M
Market cap
$5.24B
Enterprise value
$4.88B
Price to earnings (P/E)
99.07
Price to book (P/B)
5.91
Price to sales (P/S)
21.67
EV/EBIT
84.95
EV/EBITDA
75.02
EV/Sales
20.19
Revenue
$241.52M
EBIT
$57.4M
EBITDA
$65M
Free cash flow
$58.06M
Per share
Balance sheet
Liquidity
EPS
$1.84
Free cash flow per share
$2.02
Book value per share
$30.83
Revenue per share
$8.41
TBVPS
$34.21
Total assets
$982.32M
Total liabilities
$96.47M
Debt
$7.48M
Equity
$885.85M
Working capital
$623.64M
Debt to equity
0.01
Current ratio
7.97
Quick ratio
7.66
Net debt/EBITDA
-5.64
Margins
Efficiency
Dividend
EBITDA margin
26.9%
Gross margin
92.6%
Net margin
21.7%
Operating margin
11.4%
Return on assets
5.9%
Return on equity
6.3%
Return on invested capital
11.9%
Return on capital employed
6.4%
Return on sales
23.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRYS stock price
How has the Krystal Biotech stock price performed over time
Intraday
2.35%
1 week
2.76%
1 month
1.85%
1 year
80.04%
YTD
46.94%
QTD
0.14%
Financial performance
How have Krystal Biotech's revenue and profit performed over time
Revenue
$241.52M
Gross profit
$223.54M
Operating income
$27.45M
Net income
$52.37M
Gross margin
92.6%
Net margin
21.7%
The operating margin has soared by 190% from the previous quarter and by 101% YoY
The operating income has soared by 119% YoY
The net margin has soared by 106% YoY but it has plunged by 66% from the previous quarter
The net income has plunged by 51% from the previous quarter
Growth
What is Krystal Biotech's growth rate over time
Valuation
What is Krystal Biotech stock price valuation
P/E
99.07
P/B
5.91
P/S
21.67
EV/EBIT
84.95
EV/EBITDA
75.02
EV/Sales
20.19
The EPS has plunged by 51% from the previous quarter
KRYS's price to earnings (P/E) is 28% lower than its last 4 quarters average of 136.9
KRYS's P/B is 48% above its 5-year quarterly average of 4.0 and 3.7% above its last 4 quarters average of 5.7
Krystal Biotech's equity has increased by 17% YoY and by 6% QoQ
The P/S is 50% below the last 4 quarters average of 43.0
The revenue has grown by 45% since the previous quarter
Efficiency
How efficient is Krystal Biotech business performance
The ROS has soared by 107% YoY but it has plunged by 63% from the previous quarter
Krystal Biotech's ROA has plunged by 53% from the previous quarter
The ROE has plunged by 53% from the previous quarter
Krystal Biotech's return on invested capital has shrunk by 51% QoQ
Dividends
What is KRYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRYS.
Financial health
How did Krystal Biotech financials performed over time
The total liabilities has soared by 180% YoY and by 22% from the previous quarter
The company's quick ratio has shrunk by 63% YoY and by 17% QoQ
The debt is 99% less than the equity
Krystal Biotech's equity has increased by 17% YoY and by 6% QoQ
The debt has contracted by 10% YoY and by 2.7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.